These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9680114)

  • 1. Significance of chromosomal alterations and mutations of the N-RAS and TP53 genes in relation to leukemogenesis of acute myeloid leukemia.
    Misawa S; Horiike S; Kaneko H; Sasai Y; Ueda Y; Nakao M; Yokota S; Taniwaki M; Fujii H; Nakagawa H; Tsuda S; Kashima K
    Leuk Res; 1998 Jul; 22(7):631-7. PubMed ID: 9680114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53.
    Wang P; Spielberger RT; Thangavelu M; Zhao N; Davis EM; Iannantuoni K; Larson RA; Le Beau MM
    Genes Chromosomes Cancer; 1997 Nov; 20(3):282-91. PubMed ID: 9365836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
    Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetic analysis of de novo acute myeloid leukemia with trilineage myelodysplasia in comparison with myelodysplastic syndrome evolving to acute myeloid leukemia.
    Tamura S; Takemoto Y; Hashimoto-Tamaoki T; Mimura K; Sugahara Y; Senoh J; Furuyama JI; Kakishita E
    Int J Oncol; 1998 Jun; 12(6):1259-62. PubMed ID: 9592183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.
    Christiansen DH; Andersen MK; Pedersen-Bjergaard J
    J Clin Oncol; 2001 Mar; 19(5):1405-13. PubMed ID: 11230485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents.
    Andersen MK; Christiansen DH; Kirchhoff M; Pedersen-Bjergaard J
    Genes Chromosomes Cancer; 2001 May; 31(1):33-41. PubMed ID: 11284033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: an M-FISH study.
    Andersen MK; Christiansen DH; Pedersen-Bjergaard J
    Genes Chromosomes Cancer; 2005 Apr; 42(4):358-71. PubMed ID: 15645489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH.
    Schoch C; Haferlach T; Bursch S; Gerstner D; Schnittger S; Dugas M; Kern W; Löffler H; Hiddemann W
    Genes Chromosomes Cancer; 2002 Sep; 35(1):20-9. PubMed ID: 12203786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
    Fidler C; Watkins F; Bowen DT; Littlewood TJ; Wainscoat JS; Boultwood J
    Haematologica; 2004 Jul; 89(7):865-6. PubMed ID: 15257941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unbalanced translocation der(5;17) resulting in a TP53 loss as recurrent aberration in myelodysplastic syndrome and acute myeloid leukemia with complex karyotype.
    Warnstorf D; Bawadi R; Schienke A; Strasser R; Schmidt G; Illig T; Tauscher M; Thol F; Heuser M; Steinemann D; Davenport C; Schlegelberger B; Behrens YL; Göhring G
    Genes Chromosomes Cancer; 2021 Jun; 60(6):452-457. PubMed ID: 33486841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Aberrations of chromosome 5 in myeloid malignancies with complex chromosome abnormalities].
    Liu Q; Xu W; Zhu Y; Fan L; Qiu HR; Wang R; Qiao C; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1257-60. PubMed ID: 19099622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrence of point mutations in p53 gene is not increased in patients with acute myeloid leukaemia carrying an activating N-ras mutation.
    Bühler-Leclerc M; Gratwohl A; Senn HP
    Br J Haematol; 1993 Jul; 84(3):443-50. PubMed ID: 8217795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Abnormalities of chromosome 17 in myeloid malignancies with complex chromosomal abnormalities].
    Zhu Y; Xu W; Liu Q; Pan J; Qiu H; Wang R; Qiao C; Jiang Y; Zhang S; Fan L; Zhang J; Shen Y; Xue Y; Li J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Oct; 25(5):579-82. PubMed ID: 18841577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
    Lai JL; Preudhomme C; Zandecki M; Flactif M; Vanrumbeke M; Lepelley P; Wattel E; Fenaux P
    Leukemia; 1995 Mar; 9(3):370-81. PubMed ID: 7885035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype.
    Cuneo A; Bigoni R; Cavazzini F; Bardi A; Roberti MG; Agostini P; Tammiso E; Ciccone N; Mancini M; Nanni M; De Cuia R; Divona M; La Starza R; Crescenzi B; Testoni N; Rege Cambrin G; Mecucci C; Lo Coco F; Saglio G; Castoldi G
    Leukemia; 2002 Sep; 16(9):1745-51. PubMed ID: 12200689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans.
    Larson RA; Le Beau MM
    Chem Biol Interact; 2005 May; 153-154():187-95. PubMed ID: 15935816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia.
    Blau O; Hofmann WK; Baldus CD; Thiel G; Serbent V; Schümann E; Thiel E; Blau IW
    Exp Hematol; 2007 Feb; 35(2):221-9. PubMed ID: 17258071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemophagocytic syndrome preceding acute myeloid leukemia with der t [7:17][q12; q11], monosomy, 17 and 5p-.
    Tadmor T; Vadazs Z; Dar H; Laor R; Attias D
    J Pediatr Hematol Oncol; 2006 Aug; 28(8):544-6. PubMed ID: 16912598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
    Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
    Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities.
    Kaneko H; Misawa S; Horiike S; Nakai H; Kashima K
    Blood; 1995 Apr; 85(8):2189-93. PubMed ID: 7718890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.